Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
137 hedge funds and large institutions have $818M invested in Trillium Therapeutics Inc. in 2021 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 45 increasing their positions, 38 reducing their positions, and 21 closing their positions.
133% more call options, than puts
Call options by funds: $9.33M | Put options by funds: $4.01M
57% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 21
18% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 38
10% more funds holding
Funds holding: 125 → 137 (+12)
1% more capital invested
Capital invested by funds: $812M → $818M (+$6.42M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$52.8M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$17.4M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$12.8M |
| 4 |
State Street
Boston,
Massachusetts
|
+$12.4M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$7.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$19.2M |
| 2 |
CC
Commodore Capital
New York
|
-$8.55M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$7.2M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$7.11M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$6.59M |
TRIL Hedge Fund Activity: Q2 2021 in Review
137 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q2 2021, worth a combined $818M — up 0.79% from $812M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new TRIL positions and 21 closed out — a net gain of 12 holders — while 45 added to existing stakes and 38 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $52.8M. The largest seller was VR Adviser, cutting an estimated $19.2M.
- 137 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q2 2021, up from 125 in Q1 2021.
- Funds reported $818M of Trillium Therapeutics Inc. stock for Q2 2021, up 0.79% quarter-over-quarter.
- 33 funds opened new Trillium Therapeutics Inc. positions in Q2 2021 and 21 closed out, a net change of +12 holders.
- The largest Trillium Therapeutics Inc. buyer in Q2 2021 was BlackRock, an estimated $52.8M added.
- The largest Trillium Therapeutics Inc. seller in Q2 2021 was VR Adviser, an estimated $19.2M sold.
Based on aggregated 13F filings for Q2 2021.